Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Status:
Not yet recruiting
Trial end date:
2025-08-20
Target enrollment:
Participant gender:
Summary
This study aims to observe and explore the efficacy and safety of Anlotinib combined with
penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with
first-line resistance to angiogenesis inhibitors, and to summarize the treatment experience
of population.